Targeting the epidermal growth factor receptor for cancer therapy.
about
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesRole of receptor tyrosine kinases in gastric cancer: new targets for a selective therapyDifferential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancerA computational strategy to select optimized protein targets for drug development toward the control of cancer diseasesWhy do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysisEnhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.Enhanced expression of epidermal growth factor receptor gene in gastric mucosal cells by the serum derived from rats treated with electroacupuncture at stomach meridian acupointsPhase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.Clinical and scientific impact of human papillomavirus on head and neck cancer.Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.Molecular targeting to treat gastric cancer.Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks.Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?Cetuximab in non-small-cell lung cancerSquamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.Targeting the epidermal growth factor receptorBispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recyclingOncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionHER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modellingPersonalized therapy in endometrial cancer: challenges and opportunities.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyHeregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway.Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.EGF receptors as a target for cancer therapyThe role of pharmacogenetics in cancer therapeutics.Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFRThe homodimer of prostate-specific membrane antigen is a functional target for cancer therapyPhosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancerSpecific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapyThe problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities.Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer
P2860
Q27851527-BCD9B35E-7E41-4436-B4FE-DB03BB116709Q28242840-B42E1328-E434-4A25-A339-75C5C75AD636Q28477182-C59BA7CD-3567-4E9C-9A04-0C298AF84D1BQ28543105-BA85CD08-F503-41B1-A2A9-46561B4994ABQ33304557-FF61FB0B-B5EB-4AA9-87F2-51D49565757EQ33378256-69E46053-10EC-4CF5-A4E9-DA7AE159797FQ33433688-505CE93C-35DA-475D-9E43-F81E547105B7Q33693476-53CBB0B1-A8C7-4E63-8A13-D64A9623D66DQ33869583-F6C72B43-2B79-49A4-AC4D-AF6FD983AFBEQ33990908-1AEBCB0C-20FE-4BD0-BF28-FAD4CB900CE1Q33996096-DEF31139-2B46-4F6A-BF31-7C399DC681C4Q34031281-28B760B4-F8A5-4F3C-9473-89BD90FDB1DBQ34252140-DACB5A67-ECC3-47AB-9641-69AAC2D94FC2Q34326593-99E32C89-14F7-4C8D-9D1B-19CB814BD10CQ34721253-55CAC430-F99C-4FDD-B357-E1B032DAA848Q34751465-3365E78F-46FC-4879-A3E3-9BCEA3F5BB35Q34792693-3A22B438-21C4-430C-8EF1-5C2E24D6A6B5Q35200322-1A10E4E1-DF5E-438E-A58F-FA182A7387DBQ35200393-F1AEDF0F-7102-4636-A19B-1D951307AEAEQ35220347-1CF326D2-7BCC-45EC-B53B-A99D4D29A839Q35753530-5B139572-308F-4C57-9ED6-5CBB9B6B6B87Q35828552-F67357D6-911B-43B3-A036-AAC64A0C1245Q35842099-06E90BBD-BA0A-4A9E-B5F6-D0534E38D76CQ35882193-6EFBBCA0-E3F9-4F32-BDA8-1E88708AA237Q35886688-3FDA2901-4E7D-42FF-8989-8E0B7A308A0AQ35905876-2453AA80-CB60-46B4-88B4-3F31558818BFQ35911350-6421B80C-9E10-41A0-86B1-6760F871F052Q36116250-AA524B89-D5FC-4A66-8B56-96AF24E8EA49Q36117785-EA699944-E7CC-4216-95ED-E2D8E8313C99Q36146089-0DB25F83-4709-4BB2-9657-3C6CC3D2DB1BQ36321184-133EE57E-B1DF-44CA-8DF6-25704A24228EQ36489873-F8DA6B56-46FF-4C14-8344-639D74D3BAF6Q36536674-2D9260CC-AEDD-468F-8856-F9F2AACFB413Q36616502-DD32F63E-6FE4-4D49-8D84-056EAB1D33B7Q36689474-41A731E0-B515-4CCF-9575-A9E32A9E40F9Q36717778-CC9A33E3-18F0-4A34-8F80-FB220480A191Q36803657-676890C2-C333-4EB8-8949-86D3104DB27BQ36806950-ED112FF1-8B19-449C-A9B6-0A939464047FQ36983954-39D4ED13-561B-4A28-B949-179483AEBB3CQ36989648-EBA69D49-A144-4257-A068-DD8BCF131900
P2860
Targeting the epidermal growth factor receptor for cancer therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Targeting the epidermal growth factor receptor for cancer therapy.
@ast
Targeting the epidermal growth factor receptor for cancer therapy.
@en
Targeting the epidermal growth factor receptor for cancer therapy.
@nl
type
label
Targeting the epidermal growth factor receptor for cancer therapy.
@ast
Targeting the epidermal growth factor receptor for cancer therapy.
@en
Targeting the epidermal growth factor receptor for cancer therapy.
@nl
prefLabel
Targeting the epidermal growth factor receptor for cancer therapy.
@ast
Targeting the epidermal growth factor receptor for cancer therapy.
@en
Targeting the epidermal growth factor receptor for cancer therapy.
@nl
P1476
Targeting the epidermal growth factor receptor for cancer therapy.
@en
P2093
John Mendelsohn
P304
P407
P433
P577
2002-09-01T00:00:00Z